Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

What's the success rate of tigecycline in infections?

See the DrugPatentWatch profile for tigecycline

What is the success rate of tigecycline overall in infections?

There is not one single “success rate” for tigecycline because results vary a lot by infection type (for example, hospital-acquired bacterial pneumonia vs. complicated intra-abdominal infection) and by how “success” is defined in studies (clinical cure, microbiological eradication, or combined endpoints). The provided information does not include specific success-rate numbers for tigecycline across infections, so an exact rate can’t be stated from what’s available here.

Success rate by infection type: how much does it vary?

Clinically, tigecycline has been studied in multiple categories of infection, and outcomes differ by site and severity. To give a meaningful “success rate,” you typically need:
- the infection category (e.g., complicated intra-abdominal infection, skin/soft-tissue infection, hospital-acquired pneumonia),
- the study endpoint (clinical response at a defined test-of-cure time vs. microbiology),
- the patient population (severity, ICU status, prior antibiotics).

Without the underlying study data or a table of results, the success rate cannot be accurately summarized.

What endpoints do studies usually call “success” for tigecycline?

In infection trials, “success” can mean different things, such as:
- clinical cure or clinical response at a test-of-cure visit,
- combined clinical and microbiological response,
- survival-based composite outcomes in more severe infections.

Different endpoints can produce different percentages even within the same infection category.

If you tell me the infection type, can I give the right success rate?

Yes. If you share either:
- the infection type you mean (and whether it’s adults/children, ICU/non-ICU), or
- a specific study/trial name or link you’re looking at,
I can report the success rate that matches that definition.

What I need from you to answer with numbers

Please provide one of the following:
- Infection type (e.g., complicated intra-abdominal infection, pneumonia, etc.), or
- The trial/indication you’re asking about, or
- The definition of success you want (clinical cure vs combined vs microbiological).

Sources: None provided.



Other Questions About Tigecycline :

How can tigecycline overdose be identified? How does the cost of tigecycline compare to generic alternatives? What is the optimal gap between tigecycline and antacid use? Can tigecycline cause severe liver injury? What antibiotics commonly pair well with tigecycline? What bacterial infections does tigecycline treat effectively? How does improper storage affect tigecycline's efficacy?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI response’s core claim—that TYGACIL is associated with an increase in all-cause mortality and includes the label’s quantified, pooled trial findings—matches the provided FDA label text and cites the correct sections.


Category Scores

Warnings
100
Excellent

Accurate Statements

TYGACIL is associated with an increase in all-cause mortality (warning).
Supported by provided label text in Warnings/Precautions 5.1 (increase observed; includes death rates and adjusted risk difference 0.6% [95% CI 0.1, 1.2]) and reiterated in 6.1.
The label includes a quantified mortality imbalance and notes the cause is not established; the label also directs TYGACIL should be reserved when alternative treatments are not suitable.
Supported by 5.1 (cause not established; reserved for use when alternative treatments not suitable) and referenced by 5.1 cross-references to boxed warning/sections.
The pooled Phase 3/4 adjusted risk difference is 0.6% (95% CI 0.1, 1.2).
Supported by 5.1 and 6.1 (both state adjusted risk difference 0.6% with the same 95% CI).

Unsupported Statements


Contradictions


Important Omissions

No explicit mention of the restriction that TYGACIL is not indicated for hospital-acquired or ventilator-associated pneumonia (and that the mortality/efficacy issues are tied to that limitation).
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The evaluated AI content correctly reflects the on-label boxed warning concept (all-cause mortality increase) and its cited quantitative basis; it does not introduce dosing or contraindication errors.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement
Optionally include the related limitation of use statement that TYGACIL is not indicated for hospital-acquired or ventilator-associated pneumonia, which is directly tied to the mortality imbalance described in the provided label.

Drug Brand Mention Assessment

Branding Score
26
Visibility
33
Mentioned
Ranking
#1
Sentiment
35
Recommendation Status
conditional
Brand Perception
Best Known For


Core Claims
  • There is not one single “success rate” for tigecycline in infections
  • Results vary by infection type
  • Results vary by how “success” is defined in studies
  • The provided information does not include specific success-rate numbers
  • Without underlying study data or a results table, the success rate cannot be accurately summarized
Differentiators
  • Success rate varies a lot by infection type
  • Success rate varies by study endpoint definition
  • Need infection type, endpoint definition, and patient population details to report numbers

Pricing Perception: Not Mentioned